1[1]Pradhan AD,Ridker PM. Do atherosclerosis and type 2 diabetes share a common inflammatory basis[J]? Eur Heart J, 2002, 23(11):831-834.
2[2]Hansson L, Lindholm LH, Niskanen L, et al. Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension the captopril Prevention Project(CAPPP) randomised trial[J]. Lancet, 1999,353(15): 611-616.
3[3]Yusuf S,Sleight P,Pogue J,et al. Effects of an angiotensin-converting-enzyme inhibitor ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators[J]. N Engl J MED,2000,342(18) :145-153.
4[4]Grafe M,Auch-Schwelk W, Zakrzewicz A,et al. Angiotensin Ⅰinduced leukocyte adhesion on human coronary endothelial cells is mediated by E-selectin[J]. Circ Res, 1997,81 (5): 804-811.
5[5]Roger Kranzhofer, Joachim Schmidt, Carolein PH, et al. Angiotensin induces inflammatory activation of human vascular smooth muscle cells[J]. Arterioscler Thromb vasc Biol, 1999,19(7) :1623-1629.
6[6]Goossens GH,Blaak EE, Van Baak MA. Possible invovement of the adipose tissue rennin-angiotensin system in the pathophysiology of obesity and obesity-related disorders [J]. Obes Rev,2003,4(2) :43-55.
7[7]Andreas Festa, Ralph D'Agostino, George Howard ,et al. chronic subclinical infla mmation as part of the insulin resistance syndrome[J]. Circulation, 2000,102 (1): 42-47.
8[8]Johanna Helmersson,Bengt Vessby,Anders Larsson,et al. Associatlion of type 2 diabetes with cyclooxygenaae-mediated inflammation and oxidative stress in an elderly population[J]. Circulation,2004,109(14) :1729-1734.
9[9]Lechleimer M, Herold C,Dzien-Bischinger F,et al. Tumor necrosis factor-alpha plasma levels in elderly patients with type 2 diabetes mellitus abservations over 2 years[J]. Diabet Med, 2002,19(11):949-953.
2Julius S, Kjeldsen S E, Weber M, et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised tril [J]. Lancet, 2004, 363(9426): 2022-2231.
3Shao J, Iwashita N, Ikeda F, et al. Beneficial effects of candesartan, an angiotensin Ⅱ type 1 receptor blocker, on beta-cell function and morphology in db/db mice [J]. Biochem Biophys Res Commun, 2006, 344(4): 1224-1233.
4Chu K Y, Lau T, Carlsson P O, et al. Angiotensin Ⅱ type 1 receptor blockade improves beta-cell function and glucose tolerance in a mouse model of type 2 diabetes [J]. Diabetes, 2006, 55(2): 367-374.
5Grafe M, Auch-schwelk W, Zakrzewicz A, et al. Angiotensin Ⅱ induced leukocyte adhesion on human coronary endothelial cells is mediated by E-selectin [J]. Circ Res, 1997, 81(5): 804-811.
6Kranzhofer R, Schmidt J, Pfeiffer C A, et al. Angiotensin induces inflammatory activation of human vascular smooth muscle cells [J]. Arterioscler Thromb Vasc Biol, 1999, 19(7): 1623-1629.
7Leung P S, Carlsson P O. Pancreatic islet renin angiotensin system: its novel roles in islet function and in diabetes mellitus [J]. Pancreas, 2005, 30(4): 293-298.
8Yamagishi S, Nakamura K, Matsui T, et al. Potential utility of telmisartan,an angiotensin Ⅱ type 1 receptor blocker with peroxisome proliferators-activated receptor-gamma (PPAR-gamma) -modulating activity for the treatment of cardiometabolic disorders [J]. Curt Mol Med, 2007, 7(5) : 463-469.
9Younis F, Kariv N, Nachman R, et al. Telmisartan in the treatment of cohen-rosenthal diabetic hypertensive rats: the benefit of ppargamma agonism[J]. Clin Exp Hypertens, 2007, 29(6): 419-426.
10Schupp M, Janke J, Clasen R, et al. Angiotensin type 1 receptor blockers induce peroxisome proliferator-activated receptor-gamma activity [J]. Circulation, 2004, 109(17): 2054-2057.
